Trial · NCT01418209
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 21
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Any fatigue/arousal symptom | General disorders | Low-dose 17-ß-estradiol | 20 | 85 | |
| other | Any fatigue/arousal symptom | General disorders | Venlafaxine XR | 26 | 81 | |
| other | Any fatigue/arousal symptom | General disorders | Placebo | 33 | 127 | |
| other | Any central nervous system symptom | Nervous system disorders | Low-dose 17-ß-estradiol | 22 | 92 | |
| other | Any central nervous system symptom | Nervous system disorders | Venlafaxine XR | 30 | 94 | |
| other | Any central nervous system symptom | Nervous system disorders | Placebo | 36 | 142 | |
| other | Any GI symptom | Gastrointestinal disorders | Low-dose 17-ß-estradiol | 23 | 94 | |
| other | Any GI symptom | Gastrointestinal disorders | Venlafaxine XR | 25 | 93 | |
| other | Any GI symptom | Gastrointestinal disorders | Placebo | 44 | 142 | |
| other | Breast tenderness | Reproductive system and breast disorders | Low-dose 17-ß-estradiol | 5 | 90 | |
| other | Breast tenderness | Reproductive system and breast disorders | Venlafaxine XR | 0 | 93 | |
| other | Breast tenderness | Reproductive system and breast disorders | Placebo | 8 | 142 | |
| other | Vaginal secretions | Reproductive system and breast disorders | Low-dose 17-ß-estradiol | 2 | 90 | |
| other | Vaginal secretions | Reproductive system and breast disorders | Venlafaxine XR | 3 | 90 | |
| other | Vaginal secretions | Reproductive system and breast disorders | Placebo | 3 | 139 | |
| other | Any musculoskeletal symptom | Musculoskeletal and connective tissue disorders | Low-dose 17-ß-estradiol | 9 | 92 | |
| other | Any musculoskeletal symptom | Musculoskeletal and connective tissue disorders | Venlafaxine XR | 5 | 94 | |
| other | Any musculoskeletal symptom | Musculoskeletal and connective tissue disorders | Placebo | 13 | 141 | |
| other | Any miscellaneous symptom | General disorders | Low-dose 17-ß-estradiol | 28 | 94 | |
| other | Any miscellaneous symptom | General disorders | Venlafaxine XR | 36 | 94 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01418209/events